Recombinant CAMP-hMT1A reversed damage to mitochondrial ATP production, complex 1 activity, and TH expression, and reduced mitochondrial ROS levels in the MPP+/MPTP-induced PD disease model (Figs. 6 and 7). Here, CAMP is linked to Parkinson disease.